Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~25% in the premarket on Tuesday as the company disclosed the death of a patient treated with Elevidys, its FDA-approved treatment for ...
Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.
With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback